Review anchor
Signal transducer and activator of transcription 3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Signal transducer and activator of transcription 3
CHEMBL4026
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Signal transducer and activator of transcription 3 as ChEMBL target CHEMBL4026, mapped to UniProt P40763. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4026
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P40763
Signal transducer and activator of transcription 3
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Signal transducer and activator of transcription 3 matters
Signal transducer and activator of transcription 3 is reviewed as Signal transducer and activator of transcription 3 (UniProt P40763); the current evidence base includes 7 approved drugs, 2300 compounds, and 1143 assays, with lead potency reaching pChEMBL 9.0.
Protein context
Signal transducer and activator of transcription 3
Signal transducer and activator of transcription 3 Sequence length is 770 aa.
Review this target as Signal transducer and activator of transcription 3, mapped to UniProt P40763. Sequence length is 770 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P40763
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 7 approved drugs, 2300 compounds, and 1143 assays for this target. The dominant activity type is IC50. CHEMBL1389016 is the current potency anchor at pChEMBL 9.0.
Use CHEMBL1389016 as the tractability anchor when discussing potency (pChEMBL 9.0).
Activity source · ChEMBL 36 via Core Engine
7 approved
pChEMBL 9.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Signal transducer and activator of transcription 3 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P40763, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
2300
Total Compounds
1143
Total Assays
7
Approved Drugs
IC50: 1808.0, KI: 129.0, EC50: 303.0, KD: 60.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL1389016
|
9.0 | EC50 | — |
|
|
No preferred name
CHEMBL1449962
|
8.7 | EC50 | — |
|
|
No preferred name
CHEMBL5437070
|
8.6 | IC50 | — |
|
|
No preferred name
CHEMBL1703740
|
8.3 | EC50 | — |
|
|
No preferred name
CHEMBL3392776
|
8.3 | Kd | Clinical |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
DEUCRAVACITINIB
CHEMBL4435170
|
2022 |
|
|
BARICITINIB
CHEMBL2105759
|
2017 |
|
|
NICLOSAMIDE
CHEMBL1448
|
1982 |
|
|
DIGITOXIN
CHEMBL254219
|
1982 |
Source Header